Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial


Gerstein H. C., Yusuf S., Holman R. R., Bosch J., Anand S., Avezum A., ...More

LANCET, vol.368, no.9541, pp.1096-1105, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 368 Issue: 9541
  • Publication Date: 2006
  • Doi Number: 10.1016/s0140-6736(06)69420-8
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1096-1105
  • Istanbul University Affiliated: Yes

Abstract

Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drugs ability to prevent type 2 diabetes in individuals at high risk of developing the condition.